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Reverse transcription of a retroviral genome takes place in the cytoplasm of an infected cell by a process primed by a
producer-cell-derived tRNA annealed to an 18-nucleotide primer-binding site (PBS). By an assay involving primer comple-
mentation of PBS-mutated vectors we analyzed whether tRNA primers derived from the target cell can sustain reverse
transcription during murine leukemia virus (MLV) infection. Transduction efficiencies were 4–5 orders of magnitude below
those of comparable producer-cell complementations. However, successful usage of a target-cell-derived tRNA primer was
proven by cases of correction of single mismatches between Akv-MLV vectors and complementary tRNA primers toward the
primer sequence in the integrated vector. Thus, target-cell-derived tRNA-like primers are able to initiate first-strand cDNA
synthesis and plus-strand transfer leading to a complete provirus, suggesting that endogenous tRNAs from the infected cellINTRODUCTION
Retroviruses replicate through reverse transcription of
the viral RNA genome into a double-stranded DNA inter-
mediate, which is stably integrated into the host genome
as proviral DNA. The overall structure and factor compo-
sition of the complex in which reverse transcription oc-
curs are not fully understood.
Retroviral particles are competent to initiate reverse
transcription shortly after budding from the producer cell,
but there is also evidence that reverse transcription in
virions is limited (Lori et al., 1992; Trono, 1992; Arts et al.,
1994). Whereas HIV cores are disrupted shortly after
virus–cell fusion, Moloney murine leukemia virus (MLV)
cores persist longer inside the infected cells (Brown et
al., 1987; Grewe et al., 1990; Risco et al., 1995). At that
stage MLV cores are not permeable to large macromol-
ecules such as antibodies (Fassati and Goff, 1999), thus
probably preventing dilution of viral factors from the
reverse transcription complex (RTC) into the cytoplasm.
MLV-RTCs that are formed upon viral entry into the cells
contain at least the viral genome, CA, IN, RT (Fassati and
Goff, 1999), and small RNAs including tRNAs.
The host-encoded cellular tRNA in the retroviral parti-
cle serves as a primer for reverse transcription by an-
nealing of its 3 18 nucleotides (anti-PBS (Beerens et al.,
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nome sequence known as the primer-binding site (PBS).
Retroviruses differ in their use of tRNA primer and for a
given virus the PBS element and its interacting tRNA are
highly conserved (Sawyer and Dahlberg, 1973; Peters et
al., 1977; Majors and Varmus, 1983; Seiki et al., 1983;
Wain-Hobson et al., 1985). However, replication of MLV
and MLV-derived vectors is compatible with multiple
PBS–tRNA combinations in cell culture (Colicelli and
Goff, 1986; Lund et al., 1993, 1997, 2000) and in mice
(Lund et al., 1999).
The mechanisms of tRNA recruitment into the virion,
tRNA movement within the virion after internalization,
and tRNA primer placement before initiation of reverse
transcription are not well understood. While genetic
analysis based on mutagenesis studies of viral RNA and
proteins has already contributed valuable information,
investigation of the role of tRNA in vivo via mutational
analysis is hampered due to its multifunctional nature.
However, combinations of PBS-modified vectors and
complementary tRNAs have been found to be functional
in initiation of retroviral replication in MLV (Lund et al.,
1997), HIV (Yu and Morrow, 2000, 2001), and SIVmac239
(Hansen et al., 2001) in vivo. In such a “producer-cell”
complementation system (Fig. 1) a synthetic tRNA was
used to rescue the replication deficiency of a PBS-mu-
tated vector after cotransfection into producer cells and
subsequent transduction of target cells with the released
virus particles (Lund et al., 1997).
In the present report the producer-cell complementa-may also have access to the intracellular viral complex at
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the accessibility of the MLV-RTC complex for functional
tRNA-like primers derived from the target cells.
We find that the overall transduction efficiency of such
a “target-cell complementation” is 4–5 orders of magni-
tude lower than the comparable producer-cell-derived
complementation. However, we provide evidence of rare
cases in which target-cell-derived tRNA-like primers are
used as functional primers for the initiation of the first-
strand cDNA synthesis and plus-strand transfer leading
to a complete virus. This finding suggests that cellular
tRNAs may also have access to the functional viral com-




We have previously shown that replication of Akv-MLV-
derived vectors with a mutationally impaired PBS can be
restored by engineered complementary tRNA primers
(Fig. 1A), functional in both the initiation of first-strand
synthesis and second-strand transfer (Lund et al., 1997;
Modin et al., 2000; Hansen et al., 2001). In this setup
(producer-cell complementation) vector construct and
tRNA primer expressing constructs are cotransfected
into the BOSC 23 packaging cell line (Fig. 1B) (Pear et al.,
1993). Transduction titers are determined by transfer of
transiently produced virus particles to NIH 3T3 cells
followed by G418 selection. To provide genetic evidence
for tRNA usage, genomic DNA from individual NIH 3T3
colonies can be isolated and analyzed. The PBS region
of the integrated provirus derives from a DNA copy of the
PBS sequence in the original vector annealed to the
anti-PBS region of the tRNA primer at the initiation of
reverse transcription (Fig. 2B). Hence, a single marker
mutation between vector PBS (PBS-x2m) and the anti-
PBS in the tRNA (e.g., tRNAX2Pro) results in a mismatched
PBS after second-strand transfer. It may be corrected by
cellular repair systems according to either template (Fig.
2B) or, if cell division occurs before correction, segre-
gated after DNA replication. Cases of correction toward
the newly introduced engineered tRNA thereby would
clearly demonstrate the availability and usage of this
particular tRNA in the reverse transcription process.
Complementation of a PBS mutant by a tRNA-like
primer derived from the target cell (target-cell
complementation)
Here we used the potential of this complementation
system to elucidate whether the tRNA must be copack-
aged together with the viral RNA into the virion or, alter-
natively, whether it may be used for reverse transcription
when expressed in the target cell.
tRNAX2pro and tRNAX2Lys3, both able to complement the
Akv-MLV-derived vector pPBS-x2m (Hansen et al., 2001)
in the producer-cell complementation system, were
transfected (with a transfection efficiency of approxi-
mately 30%) into NIH 3T3 cells to verify expression of the
synthetic tRNAs.
Northern analysis, utilizing a probe specific for the last
18 nucleotides of the tRNAX2 variants (primer 4), verified
transient expression of both tRNAs in NIH 3T3 target
cells (Fig. 2A) and the expected size of 75/76 nts for a
trimmed and CCA-tailed tRNA. However, tRNAX2Lys3 was
expressed at higher levels (two- to threefold, Fig. 2A)
than tRNAX2Pro. As a control for loading and size, the blots
were rehybridized with a probe specific for the “anti-PBS”
of the endogenous tRNAPro (primer 5).
Pilot target-cell complementation experiments using
the vectors pPBS-x2m-neo and tRNAX2Pro/tRNAX2Lys3 re-
vealed an impairment of transduction efficiency of 4–5
orders of magnitude compared to the comparable pro-
ducer-cell complementation experiment, where vector
and complementary tRNA were copackaged (5.5  104
CFU/ml, Table 1; and Hansen et al. (2001)). Most impor-
tantly, within the G418-resistant pool of colonies (101
CFU/ml, Table 1) cases of PBS correction toward the
tRNA sequence were detected (sequence data not
shown), strongly suggesting successful usage of the
target-cell-derived tRNA.
However, the low efficiency of target-cell complemen-
tation makes the analysis sensitive to artifacts, e.g., plas-
mid contamination. Thus, various control experiments
were performed. A new vector, pPBS-x2m-EGFP-IRES-
neo, was constructed to discriminate it from vector con-
tamination with pPBS-x2m-neo and pPBS-x2-neo (Fig.
1A). In particular, pPBS-x2-neo contamination (used in
previous studies (Lund et al., 1997; Hansen et al., 2001))
could lead to misleading results, since it does not con-
tain the marker mutation compared to the tRNAX2 vari-
ants and may therefore simulate the usage of the tRNAX2
variants in reverse transcription. pPBS-x2m-neo contains
the same marker mutation as pBSx2m-EGFP-IRES-neo
but only integrated proviruses derived from the new
vector will express EGFP after successful complementa-
tion, ruling out contaminant-derived PCR amplification
from previous experiments.
In accordance with the results obtained for vector
pBS-x2m-neo the new vector pPBS-x2m-IRES-EGFP was
highly impaired in transduction efficiency (100 CFU/ml
of supernatant, Table 1). Cotransfection of the cognate
primer tRNAX2Pro in the packaging cells restored the rep-
lication capacity of the vector to a transfection efficiency
level of 1.75  104 CFU/ml of supernatant, which is
comparable to that of vector pPBS-x2m-neo (5.5  104
CFU/ml of supernatant, Table 1).
PCR-based analysis of isolated G418-resistant and
EGFP-expressing colonies revealed several cases of us-
age of the tRNAX2 variants when derived from the target
cells. In the present experiment (Fig. 2C), 4 of 12 green
colonies from NIH 3T3 cells transfected with the
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FIG. 1. The complementation system. (A) Structure of vectors and engineered tRNA primers. (Top right) Structure of the Akv-MLV-derived vectors
with emphasis on the PBS region. Nucleotide mutations differentiating PBS-Pro and PBS-x2 are shown in boldface type. The single nucleotide
difference between PBS-x2 (PstI site) and PBS-x2m (no PstI site) is indicated. (Top left) Putative cloverleaf structure of tRNAX2Pro based on the structure
of the murine tRNAPro (after Harada et al., 1979). Nucleotides mutated compared to tRNAPro (boxed) and tRNAX2Pro/tRNAX2Pro-CC (arrow) are indicated. The
anti-PBS region complementary to the PBS-x2 region is indicated (line). (Bottom) Sequences of engineered tRNA molecules. Primary sequence of a
109-bp subfragment of the endogenous murine tRNAPro gene (Russo et al., 1986) encompassed in synthetic minigenes. Nucleotides mutated in the
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tRNAX2Pro variant and 2 of 10 green colonies from trans-
fection with tRNAX2Lys3 contained the A 3 G correction
toward the target-cell-transfected tRNA primer se-
quence. This demonstrates and confirms again success-
ful complementation of the PBS-impaired vector and us-
age of target-cell-expressed tRNA to initiate reverse tran-
scription.
Four colonies (for tRNAX2Pro) or six colonies (for
tRNAX2Lys3) revealed exact identity to the input pPBS-x2m-
EGFP-IRES-neo vector. Based on the experimental setup
they originated most likely from correction of the mis-
match between PBS and tRNA toward the PBS se-
quence. Less likely they are generated by priming events
not involving tRNA/PBS complementarity. Such phenom-
ena of “low-stringency initiation of reverse transcription”
within and outside of the PBS region have been de-
scribed and investigated previously (Mikkelsen et al.,
1996, 1998; Lund et al., 2000; Modin et al., 2000) during
the analysis of producer-cell complementation experi-
ments using no complementary tRNA (also seen in Table
1). For example, the three clones containing a PBS al-
tered to PBS-pro (Fig. 2C, sequence not shown) derive
from low complementary priming with endogenous
tRNAPro as an initiation primer for RT at the PBS site. The
one single EGFP-expressing colony from mock-trans-
fected 3T3 cells transduced with pPBS-x2m-EGFP-IRES-
neo probably derives from priming outside of the ana-
lyzed region, leaving the vector PBS region unaltered
during reverse transcription.
The basis of the A/G pair at the critical PBS position of
the “mixed” clones (Fig. 2C) was not finally determined,
but most likely these colonies contain a mixed popula-
tion of at least two clones (one corrected, one not cor-
rected).
The genetic evidence for tRNA usage for initiation of
RT in the target cells was further confirmed by Southern
blot analysis of restriction enzyme-digested genomic
DNA of selected clones with PCR-predefined status (Fig.
2C, clones 1–3) at the critical PBS position. As outlined in
Fig. 1A, A 3 G correction creates a PstI site within the
PBS region (Fig. 1A) and thereby enables the sequence
determination of this position avoiding the more error-
prone PCR amplification step. For a PBS-corrected clone
toward the tRNA (clone 1), PstI digestion of the 2.24-kb
fragment, derived from additional PstI sites, leads to a
visible 1.65-kb fragment and an undetected 0.59-kb frag-
ment when hybridizing with an EGFP-specific probe (Fig.
2D). In contrast, clone 3 revealed only a 2.24-kb band and
clone 2 reveals both bands (2.24 and 1.65 kb), arguing for
the existence of both versions in this colony.
tRNAX2Pro-CC variant of tRNAX2Pro is functional in target-
cell complementation
It was shown previously in producer-cell complemen-
tation experiments using pPBS-x2-neo that cotransfec-
tion with only 1 ng tRNA-expressing plasmid results in
transduction titers of about 5–100 CFU per milliliter of
supernatant (Hansen et al., 2001). To rule out the possi-
bility that the detected complementation might be based
on contamination during the transfection of the packag-
ing cells, a new tRNAX2Pro variant was constructed. It
contains a different mismatch mutation (GC 3 CC) than
the vector pPBS-x2m (Fig. 1A).
As shown in Fig. 3A, the synthetic tRNAX2Pro-CC primer is
expressed in transfected NIH 3T3 cells. Under the mem-
brane washing conditions utilized, the hybridization
probe (primer 6) cross-hybridized to some degree to
tRNAX2Pro at a position of equal mobility, indicating that
tRNAX2Pro-CC is processed similarly to tRNAX2Pro with regard
to trimming of the tRNA precursor at the 5 and 3 termini.
Endogenous snRNPU2 (primer 10) served as a loading
control in this experiment (Hansen et al., 2001).
A target-cell complementation experiment using
ptRNAX2Pro-CC and vector pPBS-x2m-EGFP-IRES-neo re-
sulted in G418-resistant green colonies at low transduc-
tion efficiency (0.5  101 CFU per milliliter of superna-
tant, Table 1). Two clones from 20 clones analyzed
contained the GC 3 CC correction, providing genetic
evidence for tRNAX2Pro-CC primer usage to initiate reverse
transcription (Fig. 3B, bottom). The remaining clones con-
tained either a vector-like PBS (Fig. 3B, top) or a PBS-pro
(not shown) as described for pPBS-x2m-neo complemen-
tation (see above).
DISCUSSION
Retrovirus particles contain a significant number of
tRNA molecules beside other small RNAs (reviewed in
Waters and Mullin (1977)). The enrichment for specific
tRNA species in the virion in relation to the pools of
available tRNAs (Sawyer and Dahlberg, 1973; Peters et
al., 1977; Levin and Seidman, 1981; Mak et al., 1994)
suggests this situation to be more advantageous than
recruiting a tRNA derived from the target cell after infec-
tion. Among other things, the presence of a tRNA an-
nealed to the PBS may allow initiation of reverse tran-
engineered tRNAs tRNAX2Pro (Lund et al., 1997), tRNAX2Lys3 (Hansen et al., 2001), and tRNAX2Pro-CC relative to the tRNAPro gene are indicated. Elements
important for transcription are shown above the sequence. Nucleotides annealing to the PBS are underlined. (B) The complementation assay. For
producer-cell complementation experiments (I) BOSC 23 producer cells (Pear et al., 1993) are transfected with the PBS-mutated neo-vector in
cotransfection with a matching tRNA primer. Subsequently, virion-containing supernatant is used for infection of NIH 3T3 target cells. G418-resistant
colonies are counted and analyzed after 10 to 12 days of selection. For target-cell complementation (II) the vector is transfected without any matching
tRNA primer; virion-containing supernatant is transferred to NIH 3T3 cells transfected with a tRNA-primer expression plasmid prior to transduction.
G418-resistant colonies are isolated, expanded, and analyzed.
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scription shortly after entry. Using two sets of vector/
tRNA-primer combinations, we show here that tRNA-like
primers from the target cells can initiate reverse tran-
scription only with 4–5 orders of magnitude lower effi-
ciency than tRNA-like primers copackaged in the virion.
However, we demonstrate that such tRNA-like primers
from the target cells in rare cases are successfully able
to initiate reverse transcription. The limited knowledge
about the structure of MLV intracellular viral complexes
(Fassati and Goff, 1999) as well as mechanisms of nor-
mal tRNA incorporation into the viral particle prohibits a
detailed discussion of the mechanisms at this stage, but
we would like to address the following points:
Endogenous tRNA has been reported to be channeled
among components of the translation system and to be
associated with proteins at any stage of the translation
process (Stapulionis and Deutscher, 1995). Whereas
small macromolecules like Micrococcus nuclease can
enter the functional MLV-RTC complex, larger molecules
like antibodies are restricted (Fassati and Goff, 1999).
Thus, it is unlikely that tRNAs can enter the RTC when
complexed with proteins like ribosomes, elongation fac-
tors, and aminoacyl-tRNA synthetases. This may also
contribute to the low transduction efficiency seen in our
experiments. However, it was not directly proven if the
engineered tRNAs are actually complexed with proteins,
e.g., in the nucleus, during the transport from the nu-
cleus, or in the cytoplasm. Obviously, however, a subset
of tRNAs (maybe the protein-free portion) is able to
access the RTC when overexpressed in the target cell.
Posttranscriptional modifications of natural tRNAs may
play a role during the formation of the template/primer
complex by preventing additional contacts outside of the
PBS and allowing the tRNA primer to adopt a stable
structure (Fosse et al., 1998). Modifications of single
nucleotides in the engineered tRNA primers were not
determined in this study but our data show the ex-
pressed tRNAs to be processed correctly with regard to
FIG. 2. Target-cell complementation using pPBS-x2m-EGFP-IRES-neo. (A) Expression and processing properties of the engineered tRNAX2 variants.
(Top) Northern hybridization analysis of expressed engineered tRNAX2 variants. Ten g of total RNA from NIH 3T3 cells expressing the indicated tRNAs
after transfection with tRNA minigenes or empty plasmid (mock) was resolved by polyacrylamide gel electrophoresis and hybridized against an
oligonucleotide matching the 3-end of the putative tRNAX2 variants. (Bottom) Rehybridization of the same blot with an oligonucleotide probe against
endogenous tRNAPro. (B) Genetic evidence—schematic overview. tRNAX2 anneals to mismatched PBS-x2m at the initiation of transcription. The marker
mutation (arrow) results in a mismatched PBS after second-strand transfer of the reverse transcription process and may be corrected to the PBS
template or to the tRNA primer by the cellular DNA-repair machinery prior to integration. The latter case indicates successful tRNA usage and is
revealed by sequencing of the PBS region of the integrated provirus. (C) Genetic evidence for tRNAX2-primer usage in target-cell complementation
using PCR sequencing. The PBS region from genomic DNA prepared from individual isolated G418-resistant colonies from target-cell complemen-
tation experiments was PCR-amplified and sequenced. (Top) Numbers of colonies analyzed in experiments performed with the indicated vector/
tRNA-primer combinations. (Bottom) Representative examples (clones 1–3) of the sequenced PBS regions. Mismatched positions are indicated by
arrows. (D) Genetic evidence for tRNAX2 primer usage in target-cell complementation using Southern blot analysis. (Top) Genomic DNA from isolated
individual G418-resistant colonies (clones 1–3) was PstI digested, resolved by agarose gel electrophoresis, blotted, and hybridized with a probe
spanning the EGFP region as outlined in the lower panel. (Bottom) Schematic view of the integrated pBSx2m-EGFP-IRES-neo-derived provirus. The
PstI site within the PBS (boldface type) is present only after successful usage of the target-cell-derived tRNA leading to a further digestion of the 2.4-kb
PstI–PstI fragment containing the PBS region to a 1.65- and 0.59-kb fragment, respectively.
TABLE 1









pPBS-x2m-neo tRNAX2Pro 5.5  104 101
pPBS-x2m-neo tRNAX2Lys3 104d 101
pPBS-x2m-neo Mock 101 n.d.
pPBS-x2m-EGFP-IRES-neo tRNAX2Pro 1.75  104 101
pPBS-x2m-EGFP-IRES-neo Mock 100 100
Mock tRNAX2Pro n.d. 0
pPBS-x2m-EGFP-IRES-neo tRNAX2Pro-CC n.d. 0.5  101
a Producer-cell complementation experiments and target-cell complementation experiments were performed separately. n.d., not determined.
b Producer-cell complementation: NIH/3T3 cells seeded at 104 cells/cm2 were transduced with dilutions of virus particles from BOSC 23 cells
transiently transfected with 1 g of vector  9 g of tRNA plasmid.
c Target-cell complementation: NIH/3T3 cells were transiently transfected with 4 g of tRNA plasmid, reseeded at 104 cells/cm2, and transduced
with dilutions of virus particles from BOSC 23 cells transiently transfected with 10 g of vector.
d Data from Hansen et al. (2001); transfection was performed with 1 g vector  2.5 g tRNA plasmid.
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trimming of the 5 and 3 termini and CCA-tailing. Obvi-
ously, some tRNAs contains all necessary modifications
to gain access to the RTC and to initiate reverse tran-
scription. However, the possibility cannot be excluded
that an artificial modification state might favor usage of
the exogenous tRNA primers.
In vitro nucleocapsid (NC) protein has been shown to
bind preferentially to single-stranded nucleic acids and to
unwind tRNA (Karpel et al., 1987; Khan and Giedroc, 1992;
Surovoy et al., 1993) stimulating the annealing of the tRNA
primer onto the template and synthesis of minus-strand
DNA (Prats et al., 1988; Barat et al., 1989). However, the NC
activity critical to load these tRNAs to the PBS is not strictly
selective in tRNA binding. Although not directly proven for
MLV in vivo, it is conceivable that NC is present in the RTC
(Gonsky et al., 2001). If the PBS or annealing promoting
factors like NC are occupied by other tRNAs (for MLV most
likely tRNAPro), target-cell-derived tRNA must be able to
disrupt the vRNA–tRNA or tRNA–NC interactions before
reverse transcription can be initiated.
It has been shown that different reverse transcriptases
recognize specific features provided by the annealed
tRNAs (Fosse et al., 1998), but as MLV reverse transcrip-
tion can be initiated from tRNAs different from the cog-
nate tRNAPro this activity seems to be nonspecific for a
particular tRNA. Furthermore, pol products are not re-
quired for selection and placement of the tRNA primer
onto the PBS in MLV in contrast to ALV, where occupancy
of the PBS requires expression of the pol gene-coding
region (Fu et al., 1997). This relaxed specificity of tRNA
usage may also contribute to a successful target-cell
tRNA complementation.
In conclusion, we show that tRNA-like primers derived
from the target cell can support retroviral infection only at
a much lower efficiency than when the tRNA is ex-
pressed in the virus producer cells. However, we provide
unequivocal evidence for a successful usage of such
target-cell-derived tRNA primers for initiation of reverse
transcription. This new finding highlights properties of
the MLV-RTC complex in terms of tRNA accessibility and
tRNA interaction and raises the possibility of the usage
of such technology to target specific cells to be compe-
tent for viral infection. However, the observed low effi-
ciency does not support its immediate use. Future ex-
periments may address whether the efficiency of infec-
tion can be further enhanced. One possibility may be the
use of smaller RNA primers (e.g., synthetic RNA oligonu-
cleotides) provided to the target cell before infection.
MATERIALS AND METHODS
Oligonucleotides used in this study 5 3 3
The primers used in this study were as follows: Primer 1,
CGGAATTCGAAAACGAAGAAACAAAGTTTACATCTCAGT-
TGGTGGTCTAGGGG; Primer 2, AAAGCTTATAAAAACTT-
TCAGTTCCAGGGGATTTGAACCCCTG; Primer 3, GGAAA-
GCTTATAAAAACTTTCAG; Primer 4 (X2 Northern probe),
TGGTCAGCTGCAGGGGAAT; Primer 5 (Pro Northern
probe), TGGGGGCTCGTCCGGGAT; Primer 6 (X2-Pro-CC
Northern probe), TGGTCAGTTGGAGGGGATA; Primer 7,
FIG. 3. Target-cell complementation using the modified tRNAX2Pro-CC. (A) NIH 3T3 expression and processing properties of the engineered
tRNAX2Pro-CC. (Bottom) Northern hybridization analysis of expressed engineered tRNAX2 variants including tRNAX2Pro-CC. Ten g of total RNA from NIH 3T3
cells expressing the indicated tRNAs after transfection with tRNA minigenes or empty plasmid (mock) was resolved by polyacrylamide gel
electrophoresis and hybridized against an oligonucleotide matching the 3-end of tRNAX2 probe matching the 3-end of tRNAX2Pro-CC including the CCA
tail. Reduced-stringency filter-washing conditions result in some cross-hybridization to tRNAX2Pro. (Top) Filters were stripped and rehybridized against
endogenous U2 small nuclear RNA (U2snRNPU2) as loading control. Exposure times are indicated. (B) Genetic evidence for tRNAX2Pro-CC-primer usage
in target-cell complementation. The PBS region from genomic DNA prepared from individual isolated G418-resistant colonies from target-cell
complementation experiments using tRNAX2Pro-CC was PCR-amplified and sequenced. Top and bottom panels show representative examples of PBS
sequences indicating successful usage of the tRNAX2Pro-CC for initiation of reverse transcription (bottom). Mismatch position is indicated (arrow).
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TCATAAGGCTTAGCCAGCTAACTGCAG; Primer 8, GGCGC-
CCCTGCGCTGACAGCCGGAACAC; Primer 9, CGCAG-
GCGCAAAAAGTAGATGC; Primer 10 (snRNP-U2 Northern









All oligonucleotides were purchased from DNA Tech-
nology ApS, Aarhus, Denmark.
Design of vectors and engineered tRNA-like primers
pPBS-x2m-neo was described previously (Lund et al.,
1993, 1997). pPBS-x2m-EGFP-IRES-neo was constructed
by replacing the neo gene (Beck et al., 1982) cassette of
pPBS-x2m-neo with a gene cassette containing the
EGFP gene (Clontech) and an IRES-neo element (EMCV).
The constructs designed to encode the synthetic tRNA-
like primer molecules ptRNAX2Pro and ptRNAX2Lys3 were
constructed from oligonucleotides and cloned essen-
tially as described (Lund et al., 1997; Hansen et al., 2001).
ptRNAX2Pro-CC was generated by standard PCR-mediated
mutagenesis (Saiki et al., 1988) using ptRNAX2Pro as tem-
plate for primer 1 and primer 2 and subcloned in pBlue-
script.
Cell culture, transfection, and transduction
The human kidney-derived BOSC 23 packaging cell
line expressing gag–pol and env genes (Pear et al., 1993)
and NIH 3T3 mouse fibroblast cells were cultured as
described (Lund et al., 2000). BOSC 23 were transfected
essentially as described (Lund et al., 2000). For pro-
ducer-cell complementation experiments 1 g of vector
together with 9 g of tRNA-encoding plasmid was trans-
fected. For target-cell complementation studies, 10 g of
vector alone (or pUC19 mock control) was used. NIH 3T3
transfection was performed using Lipofectamine Plus
Reagent (Life Technologies) according to the instructions
provided by the manufacturer in 100-mm culture vessels
with 4 g tRNA expression plasmid or pUC19 (mock).
Transfection efficiencies were determined with an EGFP-
expressing construct (1 g) and microscopic visualiza-
tion. Transduction of untransfected NIH 3T3 cells was
performed as previously described (Lund et al., 2000).
For transduction of transfected NIH 3T3 cells, cells were
incubated at 37°C at 5% CO2 overnight, trypsinized,
counted, and reseeded at 1  104 cells/ml for transduc-
tion with one- to threefold diluted virus-containing super-
natant as described (Lund et al., 2000). G418-resistant
colonies were isolated and expanded after 10–12 days of
selection or expanded as pools.
DNA preparation and Southern hybridization
Trypsinized and pelleted cells from isolated G418-re-
sistant colonies were lysed with DNAzol and genomic
DNA was isolated according to the instructions provided
by the manufacturer (Molecular Research Center, Inc.,
Cincinnati, OH).
For Southern hybridization 5–10 g of genomic DNA
was digested by restriction enzyme (10 U per microgram
of DNA for 6 h), separated on 1% TBE agarose gel,
transferred to Zetaprobe membrane (Bio-Rad), and UV-
crosslinked (Stratalinker, Stratagene). A gel-purified DNA
probe (EGFP-containing fragment) was labeled by ran-
dom-priming using Klenow enzyme (La Roche) and
[-32P]dATP and unincorporated label was removed us-
ing Microspin G-50 (Pharmacia). Hybridizations and
washings were performed at 65°C as described previ-
ously (Sorensen et al., 1996).
RNA preparation and Northern hybridization
Total RNA from transiently transfected BOSC 23 or NIH
3T3 cells was extracted with RNA isolator (Genosys)
following the instructions provided by the manufacturer.
Subsequently the sample was DNase I digested (1 U/g;
1 h, 37°C), phenol/chloroform extracted, reprecipitated,
and dissolved in RNA storage solution (Ambion Inc.). For
Northern blot analysis total RNA (5–10 g) was sepa-
rated on denaturing 8% polyacrylamide gels and trans-
ferred to Zetaprobe membrane (Bio-Rad). Blotting and
hybridization conditions were essentially as described in
Lund et al. (1997) except that hybridization and washing
temperatures were set to 52°C for primers 4, 5, and 13.
For primer 6 the final washing time was reduced to 5 min.
As a control for the amount and integrity of RNA, the
filters were stripped (two times 20 min at 90°C in 0.1%
SSC and 0.5% SDS) and subsequently hybridized using
radiolabeled primer 5 or primer 10.
PCR analysis of transduced vectors (genetic
evidence)
Transduced primer-binding site sequences in G418-
resistant individual NIH 3T3 colonies were analyzed by
PCR. A 1.3-kb fragment (in the case of pPBS-x2m-neo) or
a 2.4-kb fragment (in the case of pPBS-x2m-EGFP-IRES-
neo) from genomic DNA was amplified using primer 7
(matching Akv-MLV positions 7838–7865) and primer 8
(matching positions 1659–1686 of the neo gene (Beck et
al., 1982)). PCR amplification parameters were as fol-
lows: 1.2 min at 94°C, 1.2 min at 60°C, and 2.5 min at
73°C for 40 cycles. PCR products were gel-purified and
directly sequenced on an automated DNA sequencer
(ABI 373 DNA sequencer, Applied Biosystems Inc.) using
primer 9 matching the Akv-MLV positions 268 to 289.
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